Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(4):235; doi:10.1093/jnci/djj087
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

NEWS

In Brief

The first 10% of the full text of this article appears below.

Intra-Abdominal Chemotherapy Recommended in Advanced Ovarian Cancer

The National Cancer Institute has issued a clinical announcement recommending a combination of intravenous (IV) and intra-abdominal chemotherapy for women with advanced ovarian cancer.

Traditional treatment for women with advanced ovarian cancer includes surgery to remove the tumor followed by IV treatment with a platinum drug such as cisplatin or carboplatin, followed by treatment with a taxane drug, such as paclitaxel. Deborah Armstrong, M.D., at the Johns Hopkins Kimmel Cancer Center in Baltimore, and colleagues conducted a clinical trial in 429 . . . [Full Text of this Article]

FDA Approves Revlimid for MDS

Prostate Cancer Screening May Not Reduce Risk of Death, Study Says

New Cervical Screening Test Works No Better than a Pap Smear

Surgery Prevents Endometrial, Ovarian Cancer In Women With Lynch Syndrome


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?